Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Tookad

- PMLiVE

J&J’s Tremfya approved by FDA for children with plaque psoriasis and psoriatic arthritis

The drug is the first IL-23 inhibitor approved for children from the age of six

- PMLiVE

Johnson & Johnson files FDA application for Tremfya in psoriatic arthritis

Approximately 125 million people globally are living with some form of psoriasis

- PMLiVE

J&J’s Tremfya approved by MHRA to treat Crohn’s disease and ulcerative colitis

Inflammatory bowel disease is estimated to affect more than 500,000 people in the UK

- PMLiVE

Johnson & Johnson shares long-term results for Tremfya in ulcerative colitis

More than 2.5 million people in Europe are affected by the inflammatory bowel disease

- PMLiVE

Johnson & Johnson’s Tremfya granted EC approval to treat ulcerative colitis in adults

More than 2.5 million people in Europe are living with the inflammatory bowel disease

- PMLiVE

Johnson & Johnson shares positive late-stage results for Tremfya in psoriatic arthritis

The inflammatory condition affects approximately 30% of psoriasis patients

- PMLiVE

Johnson & Johnson’s Tremfya recommended by CHMP to treat Crohn’s disease

Inflammatory bowel disease is estimated to affect nearly two million people across Europe

- PMLiVE

Johnson & Johnson’s Tremfya granted FDA approval to treat Crohn’s disease

An estimated three million people in the US are affected by inflammatory bowel disease

- PMLiVE

J&J receives three CHMP recommendations for immunology and oncology indications

Tremfya, Stelara and Darzalex have been recommended for ulcerative colitis, Crohn’s disease and multiple myeloma, respectively

- PMLiVE

J&J’s shares positive results for subcutaneous Tremfya in phase 3 ulcerative colitis trial

Inflammatory bowel disease affects almost one in every 100 people in the US

- PMLiVE

Johnson & Johnson’s Tremfya shows promise in ‘special site’ plaque psoriasis

The immune-mediated disease affects more than 125 million people worldwide

- PMLiVE

Johnson & Johnson’s IL-23 inhibitor Tremfya granted FDA approval for ulcerative colitis

The inflammatory bowel disease is estimated to affect more than one million people in the US

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links